Ultragenyx Pharmaceutical (RARE) News Today

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

The stock is trading lower today following mixed analyst revisions and another regulatory setback on its lead gene therapy program, overshadowing a supportive longer-term outlook from some firms.

• Positive Sentiment: William Blair maintained an "Outperform" rating on RARE and reiterated a $65.00 price target while issuing Q2 2025 EPS forecasts, signaling continued confidence in the company's growth trajectory. Equities Analysts Set Expectations for RARE Q2 Earnings
• Neutral Sentiment: January 2027 options on RARE began trading, offering investors new ways to hedge or leverage views on the stock's future volatility. January 2027 Options Now Available For Ultragenyx Pharmaceutical (RARE)
• Negative Sentiment: Morgan Stanley cut its price target on RARE to $55.00 (from $65.00) while retaining an "Overweight" rating, reflecting more cautious near-term expectations. Morgan Stanley Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $55.00
• Negative Sentiment: Wedbush trimmed its price objective on RARE shares to $34.00 (from $35.00) and assigned a "Neutral" rating, signaling tempered growth projections. Wedbush Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
• Negative Sentiment: The FDA issued a Complete Response Letter for UX111 (ABO-102) gene therapy in Sanfilippo syndrome type A, delaying approval and raising regulatory uncertainty. Ultragenyx receives complete response letter for UX111 BLA
• Negative Sentiment: A recent report noted RARE shares fell about 26% after the FDA’s rejection of its UX111 BLA, underscoring persistent investor concerns over regulatory setbacks. Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light